Qualitative behavior of systems of tumor–CD4+–cytokine interactions with treatments

Immunotherapies are important methods for controlling and curing malignant tumors. Based on recent observations that many tumors have been immuno-selected to evade recognition by the traditional cytotoxic T lymphocytes, we propose mathematical models of tumor–CD4+–cytokine interactions to investigate the role of CD4+ on tumor regression. Treatments of either CD4+ or cytokine are applied to study their effectiveness. It is found that doses of treatments are critical in determining the fate of the tumor, and tumor cells can be eliminated completely if doses of cytokine are large. Bistability is observed in models with either of the treatment strategies, which signifies that a careful planning of the treatment strategy is necessary for achieving a satisfactory outcome. Copyright © 2014 John Wiley & Sons, Ltd.

[1]  A. Perelson,et al.  Nonlinear dynamics of immunogenic tumors: parameter estimation and global bifurcation analysis. , 1994, Bulletin of mathematical biology.

[2]  M. Raffeld,et al.  Cancer Regression and Autoimmunity in Patients After Clonal Repopulation with Antitumor Lymphocytes , 2002, Science.

[3]  D. Kirschner,et al.  Modeling immunotherapy of the tumor – immune interaction , 1998, Journal of mathematical biology.

[4]  B. Quesnel Dormant tumor cells as a therapeutic target? , 2008, Cancer letters.

[5]  P. Foster,et al.  Immunotherapy of Cytotoxic T Cell–resistant Tumors by T Helper 2 Cells , 2003, The Journal of experimental medicine.

[6]  D. Earn,et al.  Interactions Between the Immune System and Cancer: A Brief Review of Non-spatial Mathematical Models , 2011, Bulletin of mathematical biology.

[7]  F. A. Goswitz,et al.  Spontaneous cyclic leukocytosis and thrombocytosis in chronic granulocytic leukemia. , 1972, The New England journal of medicine.

[8]  S. Rosenberg,et al.  Use of tumor-infiltrating lymphocytes and interleukin-2 in the immunotherapy of patients with metastatic melanoma. A preliminary report. , 1988, The New England journal of medicine.

[9]  Yuri Kogan,et al.  Improving alloreactive CTL immunotherapy for malignant gliomas using a simulation model of their interactive dynamics , 2008, Cancer Immunology, Immunotherapy.

[10]  J. Leith,et al.  Tumor micro-ecology and competitive interactions. , 1987, Journal of theoretical biology.

[11]  M. Kaplan,et al.  CD4+ T‐cell‐mediated anti‐tumor immunity can be uncoupled from autoimmunity via the STAT4/STAT6 signaling axis , 2009, European journal of immunology.

[12]  L. D. Pillis,et al.  A Validated Mathematical Model of Cell-Mediated Immune Response to Tumor Growth , 2005 .

[13]  T. Olencki,et al.  T-cell adoptive immunotherapy of metastatic renal cell carcinoma. , 1999, Urology.

[14]  Urszula Foryś,et al.  ANTI-TUMOR IMMUNITY AND TUMOR ANTI-IMMUNITY IN A MATHEMATICAL MODEL OF TUMOR IMMUNOTHERAPY , 2006 .

[15]  Olivier Lantz,et al.  CD4 cells can be more efficient at tumor rejection than CD8 cells. , 2007 .

[16]  D. Earn,et al.  Modeling anti-tumor Th1 and Th2 immunity in the rejection of melanoma. , 2010, Journal of theoretical biology.

[17]  W. S. Hlavacek,et al.  Mathematical and computational models of immune-receptor signalling , 2004, Nature Reviews Immunology.

[18]  B C Mehta,et al.  Cyclic oscillations in leukocyte count in chronic myeloid leukemia. , 1980, Acta haematologica.

[19]  H. P. de Vladar,et al.  Dynamic response of cancer under the influence of immunological activity and therapy. , 2004, Journal of theoretical biology.

[20]  J. Thompson,et al.  Adoptive T cell therapy using antigen-specific CD8+ T cell clones for the treatment of patients with metastatic melanoma: In vivo persistence, migration, and antitumor effect of transferred T cells , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[21]  S. Plesničar,et al.  Actual doubling time values of pulmonary metastases from malignant melanoma. , 1978, The Australian and New Zealand journal of surgery.

[22]  B. Kennedy,et al.  Cyclic leukocyte oscillations in chronic myelogenous leukemia during hydroxyurea therapy. , 1970, Blood.